Global Thyroid Disorder Market

Thyroid Disorder Comprehensive Study by Type (Hypothyroidism, Hyperthyroidism, Goiter, Thyroid nodules, Thyroid cancer), Treatment (Homeopathic Treatment, Ayurvedic Treatment, Other (Allelopathy)), End-User (Hospitals and clinics, Diagnostic laboratories, Research and development centers, Clinical trial firms), Diagnostic Method (TSH test, T4 tests, Thyroid antibody tests, Ultrasound, Thyroid scan, Radioactive iodine uptake test), Route Of Administration (Oral, Intravenous, Other) Players and Region - Global Market Outlook to 2027

Thyroid Disorder Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Thyroid Disorder?
Thyroid disorder is a common problem that can cause by the following symptoms due to over- or under-function of the thyroid gland. The thyroid is a small part of the body which is butterfly-shaped posses at the base of the neck below Adam’s apple. It is a part gland called the Endocrine system. This system is responsible for coordination in body and regulations of metabolism .the thyroid gland produces hormones that are responsible for the above task. Various disorders can be observed when the thyroid level is too much hormone (hyperthyroidism) or less of required (hypothyroidism). Four common disorders of the thyroid are Hashimoto’s disease, Graves’ disease, goiter, and thyroid nodules.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledPfizer (United States), AbbVie (United States), Merck (United States), RLC Labs (United States), Abbott Laboratories (United States), GSK (United Kingdom), Mylan (United States), Amgen Inc (United States), Lannet Company (United States), Novartis (Switzerland) and Allergen Company (Ireland)


The study covers a detailed analysis segmented by key business segments i.e. by type (Hypothyroidism, Hyperthyroidism, Goiter, Thyroid nodules and Thyroid cancer) and major geographies.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Thyroid Disorder market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Pfizer (United States), AbbVie (United States), Merck (United States), RLC Labs (United States), Abbott Laboratories (United States), GSK (United Kingdom), Mylan (United States), Amgen Inc (United States), Lannet Company (United States), Novartis (Switzerland) and Allergen Company (Ireland).

Market Overview:
On 3rd February 2020 CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus it will help GSK to make adjuvant technology available to support the rapid development of candidate vaccines. CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV virus. In this new move, GSK will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against 2019-nCoV.
On January 2018 FDA announced Westminster Pharmaceuticals a recall of all lots of Levothyroxine and Liothyronine (Thyroid Tablets) 15mg, 30mg, 60mg, 90mg, 120mg as the product was manufactured using active pharmaceutical ingredients (API) from a company that was found to have deviated from the Food and Drug Administration., On 9th may 2018 FDA is alerting active pharmaceutical ingredient (API) re-packagers and distributors, finished drug manufacturers, and compounders that Sichuan Friendly Pharmaceutical Co. Limited, China, has recalled all unexpired lots of porcine thyroid API due to inconsistent quality. FDA recommends that companies check their supply and quarantine any API from Sichuan Friendly. and Armour Thyroid (thyroid tablets, USP) has not been approved by the FDA as a new drug.
The thyroid disorder risk in raising the mortality rate,for these different pharmaceutical manufacturers and biotechnological manufacturers launching an effective product in the market to prevent and cure the thyroid disorder. There is a huge competition between top firms and local firms to catch the market and earn the profit and lead the business for a long time.

Influencing Trend:
New Emerging Medication For Thyroid Cancer and Radioactive Treatments Are Available

Market Growth Drivers:
Thyroid Disorder Is Increasing Due To Poor Diet and Highly Caused Due To Iodine Insufficiency Or Over Iodine Consumption

Challenges:
Thyroid Increasing Mortality Rate

Restraints:
Thyroid Surgeries Can Lead Complications And Further Side-Effects

Opportunities:
High Population Of Below Poverty Level People and Campaigns And Social Awareness About Disorder Symptoms And Causes By Different Company And Organisation

Key highlights of the Global Thyroid Disorder market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Thyroid Disorder market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Thyroid Disorder market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Thyroid Disorder Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Thyroid Disorder market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Thyroid Disorder market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Drug manufacturer, Distributor/retailer/supplier, Hospital and clinics, Pharmacies, Regulatory Agencies and Pharmaceutical Companies.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Hypothyroidism
  • Hyperthyroidism
  • Goiter
  • Thyroid nodules
  • Thyroid cancer
By Treatment
  • Homeopathic Treatment
  • Ayurvedic Treatment
  • Other (Allelopathy)

By End-User
  • Hospitals and clinics
  • Diagnostic laboratories
  • Research and development centers
  • Clinical trial firms

By Diagnostic Method
  • TSH test
  • T4 tests
  • Thyroid antibody tests
  • Ultrasound
  • Thyroid scan
  • Radioactive iodine uptake test

By Route Of Administration
  • Oral
  • Intravenous
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Thyroid Disorder Is Increasing Due To Poor Diet
      • 3.2.2. Highly Caused Due To Iodine Insufficiency Or Over Iodine Consumption
    • 3.3. Market Challenges
      • 3.3.1. Thyroid Increasing Mortality Rate
    • 3.4. Market Trends
      • 3.4.1. New Emerging Medication For Thyroid Cancer
      • 3.4.2. Radioactive Treatments Are Available
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Thyroid Disorder, by Type, Treatment, End-User, Diagnostic Method, Route Of Administration and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Thyroid Disorder (Value)
      • 5.2.1. Global Thyroid Disorder by: Type (Value)
        • 5.2.1.1. Hypothyroidism
        • 5.2.1.2. Hyperthyroidism
        • 5.2.1.3. Goiter
        • 5.2.1.4. Thyroid nodules
        • 5.2.1.5. Thyroid cancer
      • 5.2.2. Global Thyroid Disorder by: Treatment (Value)
        • 5.2.2.1. Homeopathic Treatment
        • 5.2.2.2. Ayurvedic Treatment
        • 5.2.2.3. Other (Allelopathy)
      • 5.2.3. Global Thyroid Disorder by: End-User (Value)
        • 5.2.3.1. Hospitals and clinics
        • 5.2.3.2. Diagnostic laboratories
        • 5.2.3.3. Research and development centers
        • 5.2.3.4. Clinical trial firms
      • 5.2.4. Global Thyroid Disorder by: Diagnostic Method (Value)
        • 5.2.4.1. TSH test
        • 5.2.4.2. T4 tests
        • 5.2.4.3. Thyroid antibody tests
        • 5.2.4.4. Ultrasound
        • 5.2.4.5. Thyroid scan
        • 5.2.4.6. Radioactive iodine uptake test
      • 5.2.5. Global Thyroid Disorder Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Thyroid Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. RLC Labs (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GSK (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lannet Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Allergen Company (Ireland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Thyroid Disorder Sale, by Type, Treatment, End-User, Diagnostic Method, Route Of Administration and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Thyroid Disorder (Value)
      • 7.2.1. Global Thyroid Disorder by: Type (Value)
        • 7.2.1.1. Hypothyroidism
        • 7.2.1.2. Hyperthyroidism
        • 7.2.1.3. Goiter
        • 7.2.1.4. Thyroid nodules
        • 7.2.1.5. Thyroid cancer
      • 7.2.2. Global Thyroid Disorder by: Treatment (Value)
        • 7.2.2.1. Homeopathic Treatment
        • 7.2.2.2. Ayurvedic Treatment
        • 7.2.2.3. Other (Allelopathy)
      • 7.2.3. Global Thyroid Disorder by: End-User (Value)
        • 7.2.3.1. Hospitals and clinics
        • 7.2.3.2. Diagnostic laboratories
        • 7.2.3.3. Research and development centers
        • 7.2.3.4. Clinical trial firms
      • 7.2.4. Global Thyroid Disorder by: Diagnostic Method (Value)
        • 7.2.4.1. TSH test
        • 7.2.4.2. T4 tests
        • 7.2.4.3. Thyroid antibody tests
        • 7.2.4.4. Ultrasound
        • 7.2.4.5. Thyroid scan
        • 7.2.4.6. Radioactive iodine uptake test
      • 7.2.5. Global Thyroid Disorder Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Thyroid Disorder: by Type(USD Million)
  • Table 2. Thyroid Disorder Hypothyroidism , by Region USD Million (2016-2021)
  • Table 3. Thyroid Disorder Hyperthyroidism , by Region USD Million (2016-2021)
  • Table 4. Thyroid Disorder Goiter , by Region USD Million (2016-2021)
  • Table 5. Thyroid Disorder Thyroid nodules , by Region USD Million (2016-2021)
  • Table 6. Thyroid Disorder Thyroid cancer , by Region USD Million (2016-2021)
  • Table 7. Thyroid Disorder: by Treatment(USD Million)
  • Table 8. Thyroid Disorder Homeopathic Treatment , by Region USD Million (2016-2021)
  • Table 9. Thyroid Disorder Ayurvedic Treatment , by Region USD Million (2016-2021)
  • Table 10. Thyroid Disorder Other (Allelopathy) , by Region USD Million (2016-2021)
  • Table 11. Thyroid Disorder: by End-User(USD Million)
  • Table 12. Thyroid Disorder Hospitals and clinics , by Region USD Million (2016-2021)
  • Table 13. Thyroid Disorder Diagnostic laboratories , by Region USD Million (2016-2021)
  • Table 14. Thyroid Disorder Research and development centers , by Region USD Million (2016-2021)
  • Table 15. Thyroid Disorder Clinical trial firms , by Region USD Million (2016-2021)
  • Table 16. Thyroid Disorder: by Diagnostic Method(USD Million)
  • Table 17. Thyroid Disorder TSH test , by Region USD Million (2016-2021)
  • Table 18. Thyroid Disorder T4 tests , by Region USD Million (2016-2021)
  • Table 19. Thyroid Disorder Thyroid antibody tests , by Region USD Million (2016-2021)
  • Table 20. Thyroid Disorder Ultrasound , by Region USD Million (2016-2021)
  • Table 21. Thyroid Disorder Thyroid scan , by Region USD Million (2016-2021)
  • Table 22. Thyroid Disorder Radioactive iodine uptake test , by Region USD Million (2016-2021)
  • Table 23. South America Thyroid Disorder, by Country USD Million (2016-2021)
  • Table 24. South America Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 25. South America Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 26. South America Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 27. South America Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 28. South America Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 29. Brazil Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 30. Brazil Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 31. Brazil Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 32. Brazil Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 33. Brazil Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 34. Argentina Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 35. Argentina Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 36. Argentina Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 37. Argentina Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 38. Argentina Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 39. Rest of South America Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 40. Rest of South America Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 41. Rest of South America Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 42. Rest of South America Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 43. Rest of South America Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 44. Asia Pacific Thyroid Disorder, by Country USD Million (2016-2021)
  • Table 45. Asia Pacific Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 46. Asia Pacific Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 47. Asia Pacific Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 48. Asia Pacific Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 49. Asia Pacific Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 50. China Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 51. China Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 52. China Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 53. China Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 54. China Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 55. Japan Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 56. Japan Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 57. Japan Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 58. Japan Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 59. Japan Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 60. India Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 61. India Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 62. India Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 63. India Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 64. India Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 65. South Korea Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 66. South Korea Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 67. South Korea Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 68. South Korea Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 69. South Korea Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 70. Taiwan Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 71. Taiwan Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 72. Taiwan Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 73. Taiwan Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 74. Taiwan Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 75. Australia Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 76. Australia Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 77. Australia Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 78. Australia Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 79. Australia Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 80. Rest of Asia-Pacific Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 81. Rest of Asia-Pacific Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 82. Rest of Asia-Pacific Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 83. Rest of Asia-Pacific Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 84. Rest of Asia-Pacific Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 85. Europe Thyroid Disorder, by Country USD Million (2016-2021)
  • Table 86. Europe Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 87. Europe Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 88. Europe Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 89. Europe Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 90. Europe Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 91. Germany Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 92. Germany Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 93. Germany Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 94. Germany Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 95. Germany Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 96. France Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 97. France Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 98. France Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 99. France Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 100. France Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 101. Italy Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 102. Italy Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 103. Italy Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 104. Italy Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 105. Italy Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 106. United Kingdom Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 107. United Kingdom Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 108. United Kingdom Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 109. United Kingdom Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 110. United Kingdom Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 111. Netherlands Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 112. Netherlands Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 113. Netherlands Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 114. Netherlands Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 115. Netherlands Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 116. Rest of Europe Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 117. Rest of Europe Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 118. Rest of Europe Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 119. Rest of Europe Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 120. Rest of Europe Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 121. MEA Thyroid Disorder, by Country USD Million (2016-2021)
  • Table 122. MEA Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 123. MEA Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 124. MEA Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 125. MEA Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 126. MEA Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 127. Middle East Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 128. Middle East Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 129. Middle East Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 130. Middle East Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 131. Middle East Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 132. Africa Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 133. Africa Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 134. Africa Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 135. Africa Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 136. Africa Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 137. North America Thyroid Disorder, by Country USD Million (2016-2021)
  • Table 138. North America Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 139. North America Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 140. North America Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 141. North America Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 142. North America Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 143. United States Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 144. United States Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 145. United States Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 146. United States Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 147. United States Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 148. Canada Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 149. Canada Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 150. Canada Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 151. Canada Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 152. Canada Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 153. Mexico Thyroid Disorder, by Type USD Million (2016-2021)
  • Table 154. Mexico Thyroid Disorder, by Treatment USD Million (2016-2021)
  • Table 155. Mexico Thyroid Disorder, by End-User USD Million (2016-2021)
  • Table 156. Mexico Thyroid Disorder, by Diagnostic Method USD Million (2016-2021)
  • Table 157. Mexico Thyroid Disorder, by Route Of Administration USD Million (2016-2021)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Thyroid Disorder: by Type(USD Million)
  • Table 170. Thyroid Disorder Hypothyroidism , by Region USD Million (2022-2027)
  • Table 171. Thyroid Disorder Hyperthyroidism , by Region USD Million (2022-2027)
  • Table 172. Thyroid Disorder Goiter , by Region USD Million (2022-2027)
  • Table 173. Thyroid Disorder Thyroid nodules , by Region USD Million (2022-2027)
  • Table 174. Thyroid Disorder Thyroid cancer , by Region USD Million (2022-2027)
  • Table 175. Thyroid Disorder: by Treatment(USD Million)
  • Table 176. Thyroid Disorder Homeopathic Treatment , by Region USD Million (2022-2027)
  • Table 177. Thyroid Disorder Ayurvedic Treatment , by Region USD Million (2022-2027)
  • Table 178. Thyroid Disorder Other (Allelopathy) , by Region USD Million (2022-2027)
  • Table 179. Thyroid Disorder: by End-User(USD Million)
  • Table 180. Thyroid Disorder Hospitals and clinics , by Region USD Million (2022-2027)
  • Table 181. Thyroid Disorder Diagnostic laboratories , by Region USD Million (2022-2027)
  • Table 182. Thyroid Disorder Research and development centers , by Region USD Million (2022-2027)
  • Table 183. Thyroid Disorder Clinical trial firms , by Region USD Million (2022-2027)
  • Table 184. Thyroid Disorder: by Diagnostic Method(USD Million)
  • Table 185. Thyroid Disorder TSH test , by Region USD Million (2022-2027)
  • Table 186. Thyroid Disorder T4 tests , by Region USD Million (2022-2027)
  • Table 187. Thyroid Disorder Thyroid antibody tests , by Region USD Million (2022-2027)
  • Table 188. Thyroid Disorder Ultrasound , by Region USD Million (2022-2027)
  • Table 189. Thyroid Disorder Thyroid scan , by Region USD Million (2022-2027)
  • Table 190. Thyroid Disorder Radioactive iodine uptake test , by Region USD Million (2022-2027)
  • Table 191. South America Thyroid Disorder, by Country USD Million (2022-2027)
  • Table 192. South America Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 193. South America Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 194. South America Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 195. South America Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 196. South America Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 197. Brazil Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 198. Brazil Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 199. Brazil Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 200. Brazil Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 201. Brazil Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 202. Argentina Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 203. Argentina Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 204. Argentina Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 205. Argentina Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 206. Argentina Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 207. Rest of South America Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 208. Rest of South America Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 209. Rest of South America Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 210. Rest of South America Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 211. Rest of South America Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 212. Asia Pacific Thyroid Disorder, by Country USD Million (2022-2027)
  • Table 213. Asia Pacific Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 214. Asia Pacific Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 215. Asia Pacific Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 216. Asia Pacific Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 217. Asia Pacific Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 218. China Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 219. China Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 220. China Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 221. China Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 222. China Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 223. Japan Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 224. Japan Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 225. Japan Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 226. Japan Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 227. Japan Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 228. India Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 229. India Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 230. India Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 231. India Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 232. India Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 233. South Korea Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 234. South Korea Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 235. South Korea Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 236. South Korea Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 237. South Korea Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 238. Taiwan Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 239. Taiwan Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 240. Taiwan Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 241. Taiwan Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 242. Taiwan Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 243. Australia Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 244. Australia Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 245. Australia Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 246. Australia Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 247. Australia Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 248. Rest of Asia-Pacific Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 249. Rest of Asia-Pacific Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 250. Rest of Asia-Pacific Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 251. Rest of Asia-Pacific Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 252. Rest of Asia-Pacific Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 253. Europe Thyroid Disorder, by Country USD Million (2022-2027)
  • Table 254. Europe Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 255. Europe Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 256. Europe Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 257. Europe Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 258. Europe Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 259. Germany Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 260. Germany Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 261. Germany Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 262. Germany Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 263. Germany Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 264. France Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 265. France Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 266. France Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 267. France Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 268. France Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 269. Italy Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 270. Italy Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 271. Italy Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 272. Italy Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 273. Italy Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 274. United Kingdom Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 275. United Kingdom Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 276. United Kingdom Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 277. United Kingdom Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 278. United Kingdom Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 279. Netherlands Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 280. Netherlands Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 281. Netherlands Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 282. Netherlands Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 283. Netherlands Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 284. Rest of Europe Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 285. Rest of Europe Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 286. Rest of Europe Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 287. Rest of Europe Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 288. Rest of Europe Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 289. MEA Thyroid Disorder, by Country USD Million (2022-2027)
  • Table 290. MEA Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 291. MEA Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 292. MEA Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 293. MEA Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 294. MEA Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 295. Middle East Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 296. Middle East Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 297. Middle East Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 298. Middle East Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 299. Middle East Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 300. Africa Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 301. Africa Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 302. Africa Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 303. Africa Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 304. Africa Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 305. North America Thyroid Disorder, by Country USD Million (2022-2027)
  • Table 306. North America Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 307. North America Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 308. North America Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 309. North America Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 310. North America Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 311. United States Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 312. United States Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 313. United States Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 314. United States Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 315. United States Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 316. Canada Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 317. Canada Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 318. Canada Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 319. Canada Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 320. Canada Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 321. Mexico Thyroid Disorder, by Type USD Million (2022-2027)
  • Table 322. Mexico Thyroid Disorder, by Treatment USD Million (2022-2027)
  • Table 323. Mexico Thyroid Disorder, by End-User USD Million (2022-2027)
  • Table 324. Mexico Thyroid Disorder, by Diagnostic Method USD Million (2022-2027)
  • Table 325. Mexico Thyroid Disorder, by Route Of Administration USD Million (2022-2027)
  • Table 326. Research Programs/Design for This Report
  • Table 327. Key Data Information from Secondary Sources
  • Table 328. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Thyroid Disorder: by Type USD Million (2016-2021)
  • Figure 5. Global Thyroid Disorder: by Treatment USD Million (2016-2021)
  • Figure 6. Global Thyroid Disorder: by End-User USD Million (2016-2021)
  • Figure 7. Global Thyroid Disorder: by Diagnostic Method USD Million (2016-2021)
  • Figure 8. South America Thyroid Disorder Share (%), by Country
  • Figure 9. Asia Pacific Thyroid Disorder Share (%), by Country
  • Figure 10. Europe Thyroid Disorder Share (%), by Country
  • Figure 11. MEA Thyroid Disorder Share (%), by Country
  • Figure 12. North America Thyroid Disorder Share (%), by Country
  • Figure 13. Global Thyroid Disorder share by Players 2021 (%)
  • Figure 14. Global Thyroid Disorder share by Players (Top 3) 2021(%)
  • Figure 15. Global Thyroid Disorder share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2021
  • Figure 19. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie (United States) Revenue: by Geography 2021
  • Figure 21. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck (United States) Revenue: by Geography 2021
  • Figure 23. RLC Labs (United States) Revenue, Net Income and Gross profit
  • Figure 24. RLC Labs (United States) Revenue: by Geography 2021
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 27. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GSK (United Kingdom) Revenue: by Geography 2021
  • Figure 29. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan (United States) Revenue: by Geography 2021
  • Figure 31. Amgen Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Amgen Inc (United States) Revenue: by Geography 2021
  • Figure 33. Lannet Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lannet Company (United States) Revenue: by Geography 2021
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 37. Allergen Company (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. Allergen Company (Ireland) Revenue: by Geography 2021
  • Figure 39. Global Thyroid Disorder: by Type USD Million (2022-2027)
  • Figure 40. Global Thyroid Disorder: by Treatment USD Million (2022-2027)
  • Figure 41. Global Thyroid Disorder: by End-User USD Million (2022-2027)
  • Figure 42. Global Thyroid Disorder: by Diagnostic Method USD Million (2022-2027)
  • Figure 43. South America Thyroid Disorder Share (%), by Country
  • Figure 44. Asia Pacific Thyroid Disorder Share (%), by Country
  • Figure 45. Europe Thyroid Disorder Share (%), by Country
  • Figure 46. MEA Thyroid Disorder Share (%), by Country
  • Figure 47. North America Thyroid Disorder Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • AbbVie (United States)
  • Merck (United States)
  • RLC Labs (United States)
  • Abbott Laboratories (United States)
  • GSK (United Kingdom)
  • Mylan (United States)
  • Amgen Inc (United States)
  • Lannet Company (United States)
  • Novartis (Switzerland)
  • Allergen Company (Ireland)
Additional players considered in the study are as follows:
Takeda Pharmaceutical (Japan) , Allergen Company (Ireland)
Select User Access Type

Key Highlights of Report


Jun 2023 228 Pages 66 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Thyroid Disorder Market Quantitative research analysis
Global Thyroid Disorder Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Thyroid Disorder Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Thyroid Disorder market is dominated by Players and may generate healthy valuation by 2027.
  • Thyroid Disorder Is Increasing Due To Poor Diet
  • Highly Caused Due To Iodine Insufficiency Or Over Iodine Consumption
dominated the Thyroid Disorder market. This is attributable to growing trend of "New Emerging Medication For Thyroid Cancer "

Know More About Global Thyroid Disorder Market Report?

Have a Query? Click Here

Other Related Reports

Alfuzosin Comprehensive Study by Type (5mg Tablets, 10mg Tablets), Application (Hospital, Drug store) Players and Region - Global Market Outlook to 2025
$ 3500
Mesalamine Comprehensive Study by Type (Capsule, Tablets, Rectal Enema), Application (Hospital, Pharmacies, Medical Stores), Mode of Administration (Oral, Rectal), Dosage (250 mg, 375 mg, 400 mg, 500...
$ 3350
Iron Sucrose Injection Comprehensive Study by Application (Adult, Adolescents, Geriatric, Children), Distribution Channels (Online Pharmacy, Medical Stores, Hospital Pharmacy, Others), End User (Hosp...
$ 3650
Phosphate Binder Comprehensive Study by Type (Calcium Carbonate, Calcium Acetate, Sevelamer Hydrochloride, Lanthanum Carbonate, Magnesium Hydroxide, Sucroferric Oxyhydroxide, Ferric Citrate, Others),...
$ 3650
Milk Thistle Supplement Comprehensive Study by Application (Food Industry, Cosmetic Industry, Pharmaceutical Industry), Form (Capsules, Tablets, Soft gel), Distribution Channel (Hypermarket/Supermark...
$ 3650
Cancer Hormone Therapy Drugs Comprehensive Study by Application (Treat Prostate Cancer, Breast Cancers, Endometrial Cancer, Uterine Cancer, Other Cancer Treatments), Drug (Anti-Estrogen Drugs, Aromat...
$ 3750